Obagi Confirms Unsolicited Bid from Merz Pharma

On April 2, 2012, Obagi Medical Products, Inc.

(the “Company” or “Obagi”) announced that the Obagi Board of Directors had received an unsolicited letter from Merz Pharma offering $22 per share cash to acquire the Company, and the Obagi Board of Directors will evaluate Merz Pharma's offer and the merger terms consistent with its fiduciary and legal duties. The Obagi Board of Directors realizes that time is of the essence in this matter.